Skip to main content

Table 1 Clinicopathological characteristics of 165 patients treated with neoadjuvant chemotherapy (NCT)

From: Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT)

Factors No. (%)
Total pCR non-pCR
age (years)
  ≤ 45 63 (38.18) 19 (42.22) 44 (36.67)
  > 45 102 (61.82) 26 (57.78) 76 (63.33)
BMI (kg/m2)
  < 25 121 (73.33) 35 (77.78) 86 (71.67)
  ≥ 25 44 (26.67) 10 (22.22) 34 (28.33)
Menopausal status
 Postmenopausal 77 (46.67) 22 (48.89) 55 (45.83)
 Premenopausal 88 (53.33) 23 (51.11) 65 (54.17)
Multifocality
 Multifocal 37 (22.42) 9 (20.00) 28 (23.33)
 Unifocal 128 (77.58) 36 (80.00) 92 (76.67)
Local invasion
 Yes 7 (4.24) 1 (2.22) 6 (5.00)
 No 158 (95.76) 44 (97.78) 114 (95.00)
LVI
 Absent 124 (75.15) 40 (88.89) 84 (70.00)
 Present 41 (24.85) 5 (11.11) 36 (30.00)
Clinical tumor size
 T1 19 (11.52) 6 (13.33) 13 (10.83)
 T2 123 (74.55) 32 (71.11) 91 (75.83)
 T3 23 (13.94) 7 (15.56) 16 (13.33)
Lymph node status
 N0 52 (31.52) 13 (28.89) 39 (32.50)
 N1–2 113 (68.48) 32 (71.11) 81 (67.50)
Histological grade
 I-II 53 (32.12) 12 (26.67) 41 (34.17)
 III 112 (67.88) 33 (73.33) 79 (65.83)
Histologic type
 IDC 152 (92.12) 44 (97.78) 108 (90.00)
 Others 13 (7.88) 1 (2.22) 12 (10.00)
Estrogen receptor
 Negative 111 (67.27) 38 (84.44) 73 (60.83)
 Positive 54 (32.73) 7 (15.56) 47 (39.17)
Progesterone receptor
 Negative 83 (50.30) 29 (64.44) 54 (45.00)
 Positive 82 (49.70) 16 (35.56) 66 (55.00)
Hormone receptor
 Negative 82 (49.70) 28 (62.22) 54 (45.00)
 Positive 83 (50.30) 17 (37.78) 66 (55.00)
HER2
 Negative 84 (50.91) 18 (40.00) 66 (55.00)
 Positive 81 (49.09) 27 (60.00) 54 (45.00)
Ki67
  ≤ 60% 118 (71.52) 25 (55.56) 93 (77.50)
  > 60% 47 (28.48) 20 (44.44) 27 (22.50)
Molecular subtype
 Luminal B 45 (27.27) 2 (4.44) 43 (35.83)
 HER2 enriched 69 (41.82) 27 (60.00) 42 (35.00)
 Triple negative 51 (30.91) 16 (35.56) 35 (29.17)
NCT regimen
 TEC 86 (52.12) 17 (37.78) 69 (57.50)
 TCbH 79 (47.88) 28 (62.22) 51 (42.50)
NCT time, cycles
  ≤ 4 28 (16.97) 4 (8.89) 24 (20.00)
  > 4 137 (83.03) 41 (91.11) 96 (80.00)
Hemoglobin(g/L)
  ≤ 120 42 (25.45) 6 (13.33) 36 (30.00)
  > 120 123 (74.55) 39 (86.67) 84 (70.00)
  1. Abbreviations: NCT Neoadjuvant chemotherapy, BMI body mass index, IDC Invasive ductal carcinoma, HER2 Human epidermal growth factor receptor 2, LVI lymphovascular invasion, Others: invasive lobular carcinoma, metaplastic carcinoma and medullary carcinoma, pCR pathologic complete response
\